The release of statistically significant preliminary Phase III data for United Therapeutics Inc.'s Uniprost (UT-15) positions the company to compete in the primary pulmonary hypertension market, where the only existing treatment is Glaxo Wellcome's Flolan epoprostenol intravenous prostacyclin.

Uniprost is a subcutaneously administered prostacyclin analog that acts as a vasodilator and inhibitor